Status:
SUSPENDED
Osimertinib for NSCLC With Uncommon EGFR Mutations
Lead Sponsor:
Sheba Medical Center
Collaborating Sponsors:
AstraZeneca
Conditions:
Carcinoma, Non-Small-Cell Lung
Genes, erbB-1
Eligibility:
All Genders
18-99 years
Brief Summary
This is a multi-center, retrospective study of ucEGFRmut (exon 20 insertions excluded) metastatic NSCLC osimertinib-treated as first EGFR inhibitor. RECIST and RANO-BM brain objective response rate (O...
Detailed Description
The epidermal growth factor receptor ( EGFR) is the most common targetable driver in non-small cell lung cancer (NSCLC). Approximately 90% of the EGFR mutations include an exon 19 deletion and a L858R...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Age ≥ 18 years
- NSCLC by histologic or cytologic diagnosis
- Stage IV or stage III not amendable to curative treatment (i.e., advanced disease)
- Uncommon mutation of EGFR (exon 20 insertion excluded)
- Treated with osimertinib for advanced disease as first TKI
- Osimertinib initiated not later than end of January 2021
- Exclusion criteria:
- Lack of any follow-up data
- Lack of consent for data collection or ethics committee approval for the waiver of informed consent (i.e. for deceased patients)
Exclusion
Key Trial Info
Start Date :
September 27 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05421936
Start Date
September 27 2020
End Date
September 1 2024
Last Update
November 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sheba Medical Centre
Ramat Gan, Israel, 5265601